Integra LifeSciences (NASDAQ:IART) Releases Q3 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its third quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.530-0.610 for the period, compared to the consensus earnings per share estimate of 0.560. The company issued revenue guidance of $410.0 million-$425.0 million, compared to the consensus revenue estimate of $417.3 million. Integra LifeSciences also updated its FY 2026 guidance to 2.400-2.500 EPS.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective for the company. UBS Group assumed coverage on Integra LifeSciences in a research note on Tuesday. They issued a “neutral” rating and a $19.00 target price on the stock. Truist Financial boosted their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Citigroup reiterated a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Finally, Wall Street Zen downgraded shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce” and an average price target of $18.43.

Integra LifeSciences Stock Down 11.4%

Shares of NASDAQ IART traded down $2.25 during mid-day trading on Wednesday, reaching $17.51. 732,426 shares of the company were exchanged, compared to its average volume of 894,783. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -2.72, a P/E/G ratio of 1.35 and a beta of 1.22. The firm has a 50-day moving average of $17.61 and a 200 day moving average of $13.41. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $20.49. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. The firm had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, research analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current year.

Key Stories Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Second-quarter earnings exceeded expectations. Integra reported earnings of $0.56 per share, above the $0.48 consensus estimate and up from $0.45 a year earlier. Revenue of $418.76 million was also slightly ahead of the $417.54 million estimate. Integra LifeSciences Q2 Earnings Top Estimates
• Positive Sentiment: Full-year outlook remained consistent with analyst expectations. Integra maintained fiscal 2026 EPS guidance of $2.40-$2.50, compared with the $2.45 consensus, and expects approximately $1.7 billion in revenue. Holding the outlook after the earnings beat provides some support for the company’s operating trajectory. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Third-quarter guidance was broadly in line with forecasts. Integra projected EPS of $0.53-$0.61, compared with the $0.56 consensus, and revenue of $410 million-$425 million versus the $417.3 million estimate. The midpoint of both ranges is close to Wall Street expectations, suggesting limited near-term earnings-estimate upside. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Profitability remains a concern. Despite the per-share earnings beat, Integra reported a negative net margin of 30.15%, which may temper enthusiasm about the quality and sustainability of the earnings improvement.
• Neutral Sentiment: UBS initiated coverage with a Neutral rating and a $19 price target. The target indicates modest potential upside from recent levels, but the cautious rating may limit buying interest following the earnings release. UBS Initiates Integra LifeSciences Coverage

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Integra LifeSciences by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after buying an additional 1,975 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Integra LifeSciences during the 1st quarter valued at about $277,000. Goldman Sachs Group Inc. raised its stake in shares of Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after purchasing an additional 35,790 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Integra LifeSciences by 23.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares during the period. Finally, Marshall Wace LLP acquired a new position in Integra LifeSciences in the 2nd quarter worth approximately $491,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.